One of the primary therapeutic mechanisms of anti-PD-1 therapy is through prolonged activity of anti-tumor CD8+PD-1+ T cells, which would otherwise be inhibited by PD-L1/L2 signalling within the tumor microenvironment (TME)11. This evidence concerns the gene CD274 and neoplasm.